SPOTLIGHT: TorreyPines reports success in migraine study

TorreyPines says that a Phase IIb trial of its new migraine drug--tezampanel--achieved its primary endpoint of relieving pain at doses of 40 mg. The drug did not significantly reduce pain at doses of 70 mg and 100 mg. "These data demonstrate that tezampanel unequivocally relieved migraine pain at a dose that is safe and well-tolerated," said Neil Kurtz, M.D., President and CEO of TorreyPines. Release

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.